芬蘭Aqsens Health公司及其中國(guó)合作伙伴歐際醫(yī)藥已獲得在中國(guó)江蘇省開(kāi)展的一項(xiàng)前列腺癌和膀胱癌的臨床前研究項(xiàng)目的資助。

      芬蘭圖爾庫(kù)。Aqsens Health很高興宣布與總部位于中國(guó)南京的歐際醫(yī)藥合作開(kāi)展一個(gè)新的臨床前研究項(xiàng)目。該合作研究計(jì)劃于2024年在中國(guó)江蘇省進(jìn)行前列腺癌和膀胱癌的臨床前試驗(yàn)。這項(xiàng)研究將推進(jìn)Aqsens Health的增強(qiáng)型時(shí)間分辨熒光（E-TRF）方法和生物傳感器的開(kāi)發(fā)，目的是提高從尿液中早期檢測(cè)前列腺癌和膀胱癌的能力。

      南京的這項(xiàng)合作研究建立在Aqsens在芬蘭對(duì)前列腺癌和膀胱癌檢測(cè)的廣泛研究基礎(chǔ)上，還結(jié)合了Aqsens與芬蘭圖爾庫(kù)大學(xué)醫(yī)院合作的轉(zhuǎn)移性癌癥研究項(xiàng)目的領(lǐng)先實(shí)踐。該研究項(xiàng)目計(jì)劃將持續(xù)到2024年底。

       合作的第一階段將側(cè)重于前列腺癌的臨床前試驗(yàn)，目的是為申請(qǐng)臨床試驗(yàn)許可開(kāi)展基礎(chǔ)研究。前列腺癌試驗(yàn)之后將進(jìn)行膀胱癌研究。該試驗(yàn)將與江蘇省腫瘤醫(yī)院和腫瘤專(zhuān)家合作進(jìn)行，該項(xiàng)研究將為Aqsens獲得大規(guī)模臨床試驗(yàn)許可提供支撐，并在未來(lái)中國(guó)市場(chǎng)上開(kāi)展Aqsens Health在前列腺癌和膀胱癌診斷領(lǐng)域的注冊(cè)許可。

       歐際醫(yī)藥的一個(gè)研究團(tuán)隊(duì)將接受在Aqsens實(shí)驗(yàn)室開(kāi)發(fā)體系中使用E-TRF和生物傳感器的技術(shù)培訓(xùn)，Aqsens實(shí)驗(yàn)室的開(kāi)發(fā)體系專(zhuān)門(mén)用于開(kāi)發(fā)Aqsens Health的生物傳感器、運(yùn)行E-TRF與生物傳感器分析以及培訓(xùn)研究人員。培訓(xùn)將分兩步進(jìn)行，首先是在線培訓(xùn)，然后在芬蘭圖爾庫(kù)的Aqsens Health實(shí)驗(yàn)室進(jìn)行實(shí)踐培訓(xùn)。認(rèn)證合格后，歐際醫(yī)藥的研究團(tuán)隊(duì)將能夠在Aqsens Health科學(xué)團(tuán)隊(duì)的支持下在中國(guó)進(jìn)行復(fù)雜的研究工作。

      歐際醫(yī)藥首席執(zhí)行官趙萬(wàn)洲博士表示：“我們很高興能與Aqsens Health合作，采用Aqsens Health的E-TRF和生物傳感器技術(shù)，建立創(chuàng)新手段來(lái)篩查泌尿系統(tǒng)癌癥和潛在的其他疾病。”

      趙博士還表示：“通過(guò)這種合作，我們將有效推進(jìn)健康行動(dòng)，從而在中國(guó)惡性腫瘤預(yù)防領(lǐng)域發(fā)揮一定的影響”。

      Aqsens Health的首席執(zhí)行官Timo Teimonen表示：“無(wú)創(chuàng)采樣檢測(cè)具有許多優(yōu)勢(shì)，如發(fā)現(xiàn)新的生物標(biāo)志物的可能性及效率大幅提高，研發(fā)成本大幅降低，中國(guó)對(duì)我們的E-TRF和生物傳感器表現(xiàn)出了濃厚的興趣，這些傳感器專(zhuān)門(mén)設(shè)計(jì)用于分析無(wú)創(chuàng)生物樣本。這是Aqsens Health邁出的重要一步，因?yàn)樗刮覀兡軌蚪佑|世界最大的單一市場(chǎng)?！?/span>

有關(guān)詳細(xì)信息，請(qǐng)聯(lián)系：

首席執(zhí)行官兼聯(lián)合創(chuàng)始人

Timo Tei monen

+358 40 5853105 | timo.tei monen@aqsens.com

關(guān)于：

Aqsens Health Oy是一家芬蘭醫(yī)療科技公司，開(kāi)發(fā)針對(duì)高影響疾病的非侵入性篩查測(cè)試。該公司的研究項(xiàng)目側(cè)重于開(kāi)發(fā)適合發(fā)展中經(jīng)濟(jì)體需求的基于唾液的傳染病檢測(cè)方法，并建立了準(zhǔn)確且經(jīng)濟(jì)高效的泌尿系統(tǒng)腫瘤的篩查方法。這些測(cè)試使用了Aqusens Health的新型E-TRF方法和噬菌體生物傳感器相結(jié)合的技術(shù)系統(tǒng)。

歐際醫(yī)藥是一家專(zhuān)注于醫(yī)藥創(chuàng)新和生物科學(xué)技術(shù)的公司。歐際醫(yī)藥的研究由來(lái)自不同領(lǐng)域的優(yōu)秀國(guó)際科學(xué)家團(tuán)隊(duì)領(lǐng)導(dǎo)，該公司在中國(guó)江蘇省獲得了多項(xiàng)創(chuàng)業(yè)榮譽(yù)。歐際醫(yī)藥總部位于中國(guó)南京，與中國(guó)的多家醫(yī)療機(jī)構(gòu)有著廣泛深入的合作關(guān)系。

詳情鏈接：

https://www.aqsens.com/news-and-blog/aqsens-health-og-pharma-collaboration

Aqsens Health starting pre-clinical trialsfor urinary tract cancer detection in China

Aqsens Health and its Chinese partner OG Pharmaceuticals have received funding for ajoint prostate and bladder cancer pre-clinical and clinical research project in Jiangsu Province in China.

Turku, Finland. Aqsens Health is happy to announce a new preclinical and clinical research project with OG pharmaceuticals, based in Nanjing, China. The research partnership aims to perform prostate and bladder cancer pre-clinical trials in Jiangsu Province in 2024. The study will advance  Aqsens  Health’s  E-TRF  method  and  biosensor  development  with  a  goal  to improve the early detection of prostate and bladder cancers from urine.

This research collaboration in Nanjing builds upon Aqsens' extensive research on prostate and bladder cancer detection in Finland and it also incorporates leading practices derived from Aqsens’ research  project on metastatic cancer in partnership with Turku University Hospital. The project is planned to last until the end of 2024.

The ? rst phase of the collaboration will focus on pre-clinical trials for prostate cancer with the aim to apply for permission to perform clinical trials. The prostate cancer trial will be followed by a bladder cancer study. The trials will be conducted in collaboration with Jiangsu Cancer Hospital and expert oncologists, and will enable Aqsens to obtain the permission for a large-scale clinical trial and the certi?cation of Aqsens Health’s AQ Prostate and AQ Bladder in the Chinese market.

A research team from OG Pharmaceuticals will be trained to use E-TRF and biosensor with the AQ Lab  development  environment,  which  was  purposely  built  to  be  used  in  developing Aqsens Health’s biosensors, running E-TRF and biosensor analyses, and training research personnel. The training will be conducted in two steps, ? rst online and then physically at Aqsens  Health’s  laboratories  in  Turku.  After  certi?cation  the  researchers  will  be  able  to conduct complex research work in China under the supervision of Aqsens Health’s scienti?c team.

OG Pharma quote

“We are  excited to  collaborate with Aqsens  Health  to  build  innovative  means  to screen urinary tract cancers and potentially other diseases as well using their E-TRF and biosensor technology,” says OG Pharmaceuticals CEO, Dr. Wanzhou Zhao.

“With this  collaboration  we  can  be  a  part  of  something  that  can  have  an  impact  on preventive health actions in China,” Dr. Zhao continues.

“ Non-invasive sampling   has  many  advantages,  like  the  possibility  of  discovering  new complementary  biomarkers  and  superior  cost  ef?ciency,  and  China  has  shown  strong interest  towards  our   E-TRF  and  biosensors  which  are  speci?cally  designed  to  analyze non-invasive, biological samples. This is an important step for Aqsens Health as it gives us access to the world's largest single market,“ concludes Aqsens Health’s CEO Timo Tei monen.

For more information, contact:

CEO and Co-Founder

Timo Tei monen

+358 40 5853105 | timo.tei monen@aqsens.com

About:

Aqsens Health  Oy  is  a  Finnish  med tech  startup  developing  non-invasive  screening  tests  for high-impact diseases. The company’s research projects focus on developing saliva-based infectious disease  detection  ?t  for  the  needs of  developing  economies,  and  establishing an  accurate  and cost-ef?cient urine-based screening test for urinary tract cancers. The tests use Aqsens Health’s novel E-TRF method in combination with phage-biosensors.

Nanjing OG  Pharmaceuticals  Ltd.  is  a  company  focused  on  pharmaceutical   innovations  and bioscience  technologies.  OG  P harma’s  research  is  led  by an  accomplished  international team of scientists from various ?e lds, and the company has been awarded several entrepreneurial honors in Jiangsu  Province.  OG   P harma  is  based  in  Nanjing, just  north of  Shanghai,  and works  in  broad connection with hospitals in China.